Clay Siegall is renowned for his interest in Genetics and oncology. Clay Siegall attained a B.S degree in Zoology from the University of Maryland. He later proceeded to achieve his Doctor of Philosophy in Genetics from George Washington University. From 1988 to 1991, he joined National Cancer Institute, and from 1991, he worked for Bristol-Myers Squibb Research Institute. In 1998, Dr. Siegall alongside his partner started the Seattle Genetics, and he is currently the Chairman, president, and CEO.
Dr. Siegall sits on the board of various organizations such as Mirna Therapeutics, Alder Biopharmaceuticals and, Ultragenyx Pharmaceuticals and a member of Compensation Committee. His interest and training in science have stressed on involved to possible cancer therapies available. Under his leadership, Seattle Genetics has become the top researcher in antibody cancer curing method.
The Seattle Genetics
Based in Seattle, Washington, Seattle Genetics focuses its attention on the growth and sale of advanced antibodies that can be used to cure cancer. The company has been analyzing, controlling and putting medicine into packages. Some of its recognized drug includes Adcetris. It uses the Lego Bricks found in its lobby as a symbol of the company’s capability of being a linkage of antibodies. The cancer cell is ruined from within it by the antibodies, a scheme that could put Seattle genetics together with the big shots in the industry.
Founded in 1998 by Dr. Clay Siegall, Seattle Genetics vision is to be in the midst of the few organizations that are finely tuned from biotechnology companies to large pharmaceutical ones. The recruiting of 200 extra employees this year is foreseen as the firm intends on putting into place more research and marketing measures.
However, if the Adcetris drug known to deal with cancer of the lymph known as Hodgkin lymphoma proves to work, then the Seattle Genetics could increase its Sales. The company president discourages any chance of selling the company and is still working on developing the already listed drugs of interest. Seattle Genetics has spread in global marketing by stating a base in Switzerland. To acquire more knowledge, Seattle Generic has partnered with Takeda Company.
The CEO, Mr. Seigall predicts that four of the 11 drugs that are being developed by Seattle Genetics are more likely to prosper in the market. With the Adcetris already given the green light by the Food and Drug Administration, this could drive the sales hitting a high of $1billion.